(d) Percutaneous transluminal coronary angioplasty (PTCA) balloon catheters.

d) nahka läbivad transluminaalsed koronaarangioplastiaks kasutatavad balloonkateetrid

(c) Coronary guiding catheters,(d) Percutaneous transluminal coronary angioplasty (PTCA) balloon catheters,

d) nahka läbivad transluminaalsed koronaarangioplastiaks (Percutaneous transluminal coronary angioplasty (PTCA)) kasutatavad balloonkateetrid

Major cardiovascular events (fatal and non-fatal AMI, silent MI, acute CHD death, unstable angina, CABG, PTCA, revascularization, stroke)
http://www.emea.europa.eu/

Tõsine kardiovaskulaarne sündmus (fataalne ja mittefataalne AMI, tumm MI, äge CHD surm, ebastabiilne stenokardia, CABG, PTCA, revaskularisatsioon, insult)
http://www.emea.europa.eu/

AMI = acute myocardial infarction; CABG = coronary artery bypass graft; CHD = coronary heart disease; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty.
http://www.emea.europa.eu/

AMI=äge müokardiinfarkt; CABG=koronaararteri šuntsiirik; CHD=südame isheemiatõbi; MI=müokardiinfarkt; PTCA=perkutaanne transluminaalne koronaarangioplastika.
http://www.emea.europa.eu/

The patients more likely to benefit from a treatment with INTEGRILIN are those who have had acute angina and may have a special type of surgery to clear up the arteries to the heart (percutaneous transluminal coronary angiography, or PTCA).
http://www.emea.europa.eu/

Ravi INTEGRILINiga on tõenäoliselt kasulikum patsientidele, kellel on olnud äge stenokardia ja kellel võidakse südame pärgartereid vabastada erilist liiki operatsiooniga (pärgarteri balloonlaiendus (PTCA), angioplastia liik).
http://www.emea.europa.eu/

Another study, ESPRIT, compared INTEGRILIN with a placebo in 2,000 patients who were having PTCA to remove a blood clot from the coronary arteries and insert a stent (a short tube that remains in the artery to stop it closing).
http://www.emea.europa.eu/

Teises uuringus ESPRIT võrreldi INTEGRILINi platseeboga 2000 patsiendil, kellel viidi läbi PTCA, et eemaldada südame pärgarteritest tromb ja paigaldada stent (lühike arterisse jäetav toru, mis takistab selle sulgumist).
http://www.emea.europa.eu/

Patients most likely to benefit from INTEGRILIN treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty) (see section 5.1).
http://www.emea.europa.eu/

INTEGRILIN- ravist saavad enam kasu patsiendid, kellel esineb müokardi infarkti tekkimise kõrge risk esimese 3... 4 päeva jooksul pärast ägedate stenokardia sümptomite tekkimist, sh näiteks need patsiendid, kellele tõenäoliselt teostatakse varane PTKA (perkutaanne transluminaalne koronaarangioplastika) (vt lõik 5. 1).
http://www.emea.europa.eu/

(8) Concerning the accessories coronary guiding catheters, coronary steerable guidewires, coronary PTCA balloon catheters, the Commission’s market inquiry has established that each of these products constitutes a separate relevant product market. Most interventions will require a specific set of accessories, with different dimensions and shape.

(8) Komisjoni turu-uuringuga tehti kindlaks, et nii koronaararteri kateteerimise juhtetraadid, suunatavad juhtetraadid kui ka nahka läbivad transluminaalsed koronaarangioplastias kasutatavad balloonkateetrid moodustavad igaüks eraldi tooteturu. Enamiku raviprotseduuride jaoks kasutatakse erinevaid tarvikuid, millel igaühel on eri mõõdud ja kuju.

The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
http://www.emea.europa.eu/

Primaarse tulemusnäitajaga patsientide arv [kardiovaskulaarne (CV) surm, müokardiinfarkt (MI) või insult] oli klopidogreeli rühmas 582 (9, 3%) ja platseeborühmas 719 (11, 4%), 20% - line suhtelise riski langus (95% CI 10... 28%; p=0, 00009) klopidogreeli rühmas (17% - line suhtelise riski langus konservatiivset ravi saanud patsientidel, 29% kui neil oli perkutaanne transluminaalne koronaaride angioplastika (PTKA) ilma või koos stendiga ja 10% kui neil teostati koronaararterite šunteerimine (KAŠ)).
http://www.emea.europa.eu/

19 The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG)).
http://www.emea.europa.eu/

Primaarse tulemusnäitajaga patsientide arv [kardiovaskulaarne (CV) surm, müokardiinfarkt (MI) või insult] oli klopidogreeli rühmas 582 (9, 3%) ja platseeborühmas 719 (11, 4%), 20% - line suhtelise riski langus (95% CI 10... 28%; p=0, 00009) klopidogreeli rühmas (17% - line suhtelise riski langus konservatiivset ravi saanud patsientidel, 29% kui neil oli perkutaanne transluminaalne koronaaride angioplastika (PTKA) ilma või koos stendiga ja 10% kui neil teostati koronaararterite šunteerimine
http://www.emea.europa.eu/